Leptin secretion and severity of glycemic disorders in women with body weight excess
https://doi.org/10.14341/2072-0351-3758
Abstract
Aim.
To characterize leptin secretion in fasting state and upon intravenous glucose administration in patients with type 2 diabetes mel- litus (T2DM), prediabetes and obesity.
Materials and methods.
59 female patients took part in this study: 12 had no signs of glycemic disorder, 18 were diagnosed with prediabetes and 30 ? with newly diagnosed T2DM. Median age was 54 [48.6?60] years, median BMI ? 33.2 [29.0?37.2] kg/m2. All participants were tested for fasting leptin, fasting insulin and blood glucose levels. Prediabetic and diabetic subjects also received a bolus intravenous injection of 40% glucose solution (0.75 g/kg of body mass) with subsequent additional measurement of insulin levels at 2, 70 and 120 min upon injection, and leptin levels ? at 120 min.
Results.
Median fasting leptin in obese and patients with weight excess was 42.0 [22?60] ng/mL, which is about 2 times higher than normal reference maximum (27.6 ng/mL). Subjects with prediabetes and T2DM showed significantly lower median fasting leptin levels of 29.1 ng/mL [13.5?45.7] and 21.3 [14.3?42.2], respectively (p <0.05). After 2 h upon glucose administration we observed a statistically significant reduction in leptin level in both groups as compared to fasting state (p <0.05). In patients with prediabetes the drop reached 23.3% against 15.3% in diabetic subjects (p <0.05). Both groups demonstrated positive correlation between plasma leptin reduction and insulin area under the curve (AUC) during intravenous glucose tolerance test (r=0.4, р <0.05).
Conclusion.
1) Plasma leptin levels are increased in obese women with normal glucose tolerance (42.0 [22.0?60.0] ng/mL) and sig- nificantly decrease upon development of prediabetes or overt T2DM, which is likely associated with progression of insulin defi- ciency. 2) Leptin drop during intravenous glucose tolerance test was found to be in direct dependence with insulinemia and appeared more prominent in patients with prediabetes than in diabetics (23.1% and 11%, respectively, р=0.02).
To characterize leptin secretion in fasting state and upon intravenous glucose administration in patients with type 2 diabetes mel- litus (T2DM), prediabetes and obesity.
Materials and methods.
59 female patients took part in this study: 12 had no signs of glycemic disorder, 18 were diagnosed with prediabetes and 30 ? with newly diagnosed T2DM. Median age was 54 [48.6?60] years, median BMI ? 33.2 [29.0?37.2] kg/m2. All participants were tested for fasting leptin, fasting insulin and blood glucose levels. Prediabetic and diabetic subjects also received a bolus intravenous injection of 40% glucose solution (0.75 g/kg of body mass) with subsequent additional measurement of insulin levels at 2, 70 and 120 min upon injection, and leptin levels ? at 120 min.
Results.
Median fasting leptin in obese and patients with weight excess was 42.0 [22?60] ng/mL, which is about 2 times higher than normal reference maximum (27.6 ng/mL). Subjects with prediabetes and T2DM showed significantly lower median fasting leptin levels of 29.1 ng/mL [13.5?45.7] and 21.3 [14.3?42.2], respectively (p <0.05). After 2 h upon glucose administration we observed a statistically significant reduction in leptin level in both groups as compared to fasting state (p <0.05). In patients with prediabetes the drop reached 23.3% against 15.3% in diabetic subjects (p <0.05). Both groups demonstrated positive correlation between plasma leptin reduction and insulin area under the curve (AUC) during intravenous glucose tolerance test (r=0.4, р <0.05).
Conclusion.
1) Plasma leptin levels are increased in obese women with normal glucose tolerance (42.0 [22.0?60.0] ng/mL) and sig- nificantly decrease upon development of prediabetes or overt T2DM, which is likely associated with progression of insulin defi- ciency. 2) Leptin drop during intravenous glucose tolerance test was found to be in direct dependence with insulinemia and appeared more prominent in patients with prediabetes than in diabetics (23.1% and 11%, respectively, р=0.02).
About the Authors
Alexander Vasil'evich Dreval'
Moscow Regional Research Clinical Institute,Moscow
d.m.n., prof., rukovoditel' otdeleniya terapevticheskoy endokrinologii
d.m.n., prof., rukovoditel' otdeleniya terapevticheskoy endokrinologii
Irina Vladimirovna Trigolosova
Moscow Regional Research Clinical Institute,Moscow
d.m.n., v.n.s. otdeleniya terapevticheskoy endokrinologii
d.m.n., v.n.s. otdeleniya terapevticheskoy endokrinologii
Inna Vladimirovna Misnikova
Moscow Regional Research Clinical Institute,Moscow
vrach otdeleniya terapevticheskoy endokrinologii
vrach otdeleniya terapevticheskoy endokrinologii
References
1. Дедов ИИ, Мельниченко ГА, Романцова ТИ. Патогенетические аспекты ожирения. Ожирение и метаболизм. 2004; (1):3–9.
2. Flanagan DE, Vaile JC, Petley GW, Phillips DI, Godsland IF, Owens P, Moore VM, Cockington RA, Robinson JS. Gender differences in the relationship between leptin, insulin resistance and the autonomic nervous system. Regul Pept. 2007 Apr 5;140(1–2):37–42.
3. Ceddia RB, Koistinen HA, Zierath JR, Sweeney G. Analysis of paradoxical observations on the association between leptin and insulin resistance. FASEB J. 2002 Aug;16(10):1163–1176.
4. Toyoshima Y, Gavrilova O, Yakar S, Jou W, Pack S, Asghar Z, Wheeler MB, LeRoith D. Leptin improves insulin resistance and hyperglycemia in a mouse model of type 2 diabetes. Endocri- nology. 2005 Sep;146(9):4024–4035.
5. Unger R. Lipotoxic Diseases. Annu Rev Med. 2002;53:319–336.
6. Bray GA. Etiology and pathogenesis of obesity. Clin Cornerstone. 1999;2(3):1–15.
7. Casabiell X, Piñeiro V, Peino R, Lage M, Camiña J, Gallego R, Vallejo LG, Dieguez C, Casanueva FF. Gender differences in both spontaneous and stimulated leptin secretion by human omental adipose tissue in vitro: dexamethasone and estradiol stimulate leptin release in women, but not in men. J Clin Endocri- nol Metab. 1998 Jun;83(6):2149–2155.
8. Buyukbese MA, Cetinkaya A, Kocabas R, Guven A, Tarakcioglu M. Leptin levels in obese women with and without type 2 diabetes mellitus. Mediators Inflamm. 2004 Dec;13(5–6):321–325.
9. Sandhofer A, Laimer M, Ebenbichler CF, Kaser S, Paulweber B, Patsch JR. Soluble leptin receptor and soluble receptor-bound fraction of leptin in the metabolic syndrome. Obes Res. 2003 Jun;11(6):760–768.
10. Iritani N, Sugimoto T, Fukuda H. Gene expressions of leptin, insulin receptors and lipogenic enzymes are coordinately regulated by insulin and dietary fat in rats. J Nutr. 2000 May;130(5):1183–1138.
11. Levy JR, Stevens W. The effects of insulin, glucose, and pyruvate on the kinetics of leptin secretion. Endocrinology. 2001 Aug;142(8):3558–3562.
12. Sivitz WI, Wayson SM, Bayless ML, Larson LF, Sinkey C, Bar RS, Haynes WG. Leptin and body fat in type 2 diabetes and monodrug therapy. J Clin Endocrinol Metab. 2003 Apr;88(4):1543–1553.
13. Masuo K, Katsuya T, Ogihara T, Tuck ML. Acute hyperinsulinemia reduces plasma leptin levels in insulin-sensitive japanese men. Am J Hypertens. 2005 Feb;18(2 Pt 1):235–243.
Review
For citations:
Dreval' A.V., Trigolosova I.V., Misnikova I.V. Leptin secretion and severity of glycemic disorders in women with body weight excess. Diabetes mellitus. 2013;16(2):67-72. (In Russ.) https://doi.org/10.14341/2072-0351-3758
Views:
10951
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND 4.0).
Email this article 
